COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
01 déc. 2021 07h00 HE
|
COMPASS Pathways
- Positive topline results validated by additional analyses - Patient improvements beyond reduction of depression symptoms - Further insights into timing and circumstance of adverse...
COMPASS Pathways to participate in upcoming Evercore, H.C. Wainwright & Berenberg investor conferences
30 nov. 2021 08h00 HE
|
COMPASS Pathways
LONDON, Nov. 30, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways granted fifth US patent for crystalline psilocybin
23 nov. 2021 07h00 HE
|
COMPASS Pathways
London, UK - 23 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021
09 nov. 2021 07h18 HE
|
COMPASS Pathways
Highlights: Positive topline results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression; rapid and sustained response for patients receiving a single 25mg dose of...
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
09 nov. 2021 07h00 HE
|
COMPASS Pathways
Largest randomised, controlled, double-blind psilocybin therapy study ever completedshows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological...
COMPASS Pathways plc to announce third quarter 2021 financial results on 9 November 2021
08 nov. 2021 07h00 HE
|
COMPASS Pathways
London, U.K., Nov. 08, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder
03 nov. 2021 08h00 HE
|
COMPASS Pathways
London, UK – 3 November 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...
Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups
20 oct. 2021 09h00 HE
|
COMPASS Pathways
Investigator-initiated study shows remission in major depression symptoms for 50% of participants London, UK – 20 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health...
COMPASS Pathways is granted new US patent for crystalline psilocybin
19 oct. 2021 07h00 HE
|
COMPASS Pathways
London, UK – 19 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health,...
COMPASS Pathways to participate in upcoming Maxim and Cantor investor conferences
21 sept. 2021 08h00 HE
|
COMPASS Pathfinder Ltd.
London, UK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...